Methylphenidate
( DrugBank: Methylphenidate / KEGG DRUG: Methylphenidate hydrochloride, Methylphenidate )
7 diseases
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 6 | パーキンソン病 | 8 |
| 13 | 多発性硬化症／視神経脊髄炎 | 5 |
| 34 | 神経線維腫症 | 1 |
| 84 | サルコイドーシス | 3 |
6. パーキンソン病
臨床試験数 : 2,817 / 薬物数 : 2,606 - (DrugBank : 348) / 標的遺伝子数 : 185 - 標的パスウェイ数 : 205
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
13. 多発性硬化症／視神経脊髄炎
臨床試験数 : 3,898 / 薬物数 : 2,785 - (DrugBank : 360) / 標的遺伝子数 : 265 - 標的パスウェイ数 : 239
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
34. 神経線維腫症
臨床試験数 : 179 / 薬物数 : 259 - (DrugBank : 84) / 標的遺伝子数 : 90 - 標的パスウェイ数 : 211
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
84. サルコイドーシス
臨床試験数 : 196 / 薬物数 : 261 - (DrugBank : 78) / 標的遺伝子数 : 73 - 標的パスウェイ数 : 183
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
113. 筋ジストロフィー
臨床試験数 : 826 / 薬物数 : 680 - (DrugBank : 126) / 標的遺伝子数 : 86 - 標的パスウェイ数 : 188
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
179. ウィリアムズ症候群
臨床試験数 : 12 / 薬物数 : 21 - (DrugBank : 8) / 標的遺伝子数 : 9 - 標的パスウェイ数 : 35
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
206. 脆弱Ｘ症候群
臨床試験数 : 124 / 薬物数 : 103 - (DrugBank : 35) / 標的遺伝子数 : 58 - 標的パスウェイ数 : 84
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|